Table 7.
Risk for mortality in survivors of acute exacerbation of interstitial lung disease
| Parameter | Univariate analysis | Multivariate analysisa | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| IPF | 2.06 (1.27 − 3.32) | 0.003 | 1.64 (0.99 − 2.72) | 0.053 |
| Age | 1.04 (1.00 − 1.08) | 0.026 | 1.02 (0.99 − 1.05) | 0.246 |
| Male gender | 1.21 (0.75 − 1.95) | 0.446 | 1.10 (0.66 − 1.82) | 0.721 |
| Non-elective respiratory re-hospitalisation(s) before follow-up visit | 2.22 (1.36 − 3.61) | 0.001 | 2.08 (1.25 − 3.45) | 0.005 |
| Glucocorticoid dose at least 30 mg per day at hospital discharge | 0.81 (0.51 − 1.27) | 0.357 | 0.68 (0.42 − 1.10) | 0.112 |
| Discharge disposition home | 0.85 (0.54 − 1.34) | 0.490 | 1.11 (0.65 − 1.89) | 0.697 |
| Supplementary oxygen needed at discharge | 1.62 (1.00 − 2.62) | 0.050 | 1.42 (0.86 − 2.32) | 0.171 |
| DLCO% predicted | 0.996 (0.98 − 1.01) | 0.648 | 0.994 (0.98 − 1.01) | 0.524 |
| FVC% predicted | 0.997 (0.981 − 1.014) | 0.739 | 0.802 (0.53 − 1.21) | 0.292 |
aMultivariate analysis included IPF, age, non-elective respiratory re-hospitalisation in 12 months, supplementary oxygen needed at discharge. Abbreviations: CI Confidence interval, DLCO Diffusion capacity for carbon monoxide, FVC Forced vital capacity, HR Hazard ratio, IPF Idiopathic pulmonary fibrosis